Joel Greenblatt’s RMD Holdings & Trades

First Buy
Q2 2013
Duration Held
50 Quarters
Largest Add
Q1 2014
+295,129 shares
Current Position
50,705 shares
$13.88 M value

Joel Greenblatt's RMD Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 50.7K shares of ResMed Inc. (RMD) worth $13.88 M, representing 0.06% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.

Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in RMD, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2014, adding 295.1K shares. Largest reduction occurred in Q2 2014, reducing 511.7K shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's ResMed (RMD) Holding Value Over Time

Track share changes against reported price movement

Quarterly ResMed (RMD) Trades by Joel Greenblatt

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2013 +56,318 Add 0.00% 56,317 $45.14
Q3 2013 -31,125 Reduce 55.27% 25,192 $52.83
Q4 2013 +209,695 Add 832.39% 234,887 $47.08
Q1 2014 +295,129 Add 125.65% 530,016 $44.69
Q2 2014 -511,695 Reduce 96.54% 18,321 $50.65
Q3 2014 -18,321 Sold Out 18,321 $0.00
Q3 2015 +4,210 New Buy 4,210 $51.07
Q4 2015 -4,210 Sold Out 4,210 $0.00
Q1 2016 +112,449 New Buy 112,449 $57.82
Q2 2016 +150,509 Add 133.85% 262,958 $63.23
Q3 2016 +33,425 Add 12.71% 296,383 $64.79
Q4 2016 -283,450 Reduce 95.64% 12,933 $62.01
Q1 2017 -3,218 Reduce 24.88% 9,715 $71.95
Q2 2017 -9,715 Sold Out 9,715 $0.00
Q4 2017 +4,751 New Buy 4,751 $84.61
Q1 2018 -4,751 Sold Out 4,751 $0.00
Q2 2018 +74,711 New Buy 74,711 $103.59
Q3 2018 +101,291 Add 135.58% 176,002 $115.34
Q4 2018 -114,490 Reduce 65.05% 61,512 $113.86
Q1 2019 -55,711 Reduce 90.57% 5,801 $103.95
Q2 2019 -5,801 Sold Out 5,801 $0.00
Q3 2019 +4,459 New Buy 4,459 $135.01
Q4 2019 -4,459 Sold Out 4,459 $0.00
Q1 2020 +4,160 New Buy 4,160 $147.36
Q2 2020 -3,049 Reduce 73.29% 1,111 $191.72
Q3 2020 +32,153 Add 2894.06% 33,264 $171.42
Q4 2020 -20,408 Reduce 61.35% 12,856 $212.59
Q1 2021 -12,856 Sold Out 12,856 $0.00
Q4 2021 +6,562 New Buy 6,562 $260.44
Q1 2022 -5,473 Reduce 83.40% 1,089 $242.42
Q2 2022 -44 Reduce 4.04% 1,045 $209.57
Q3 2022 -52 Reduce 4.98% 993 $218.53
Q4 2022 +12 Add 1.21% 1,005 $208.13
Q1 2023 -1,005 Sold Out 1,005 $0.00
Q2 2023 +3,579 New Buy 3,579 $218.50
Q3 2023 +10,196 Add 284.88% 13,775 $147.87
Q4 2023 -2,396 Reduce 17.39% 11,379 $172.02
Q1 2024 +13,971 Add 122.78% 25,350 $198.03
Q2 2024 +18,851 Add 74.36% 44,201 $191.42
Q3 2024 +2,242 Add 5.07% 46,443 $244.12
Q4 2024 -20,563 Reduce 44.28% 25,880 $228.69
Q1 2025 -6,935 Reduce 26.80% 18,945 $223.85
Q2 2025 -7,275 Reduce 38.40% 11,670 $258.00
Q3 2025 +39,035 Add 334.49% 50,705 $273.73

Joel Greenblatt's ResMed Investment FAQs

Joel Greenblatt first purchased ResMed Inc. (RMD) in Q2 2013, acquiring 56,317 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held ResMed Inc. (RMD) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt's largest addition to ResMed Inc. (RMD) was in Q1 2014, adding 530,016 shares worth $23.69 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 50,705 shares of ResMed Inc. (RMD), valued at approximately $13.88 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, ResMed Inc. (RMD) represents approximately 0.06% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt's peak holding in ResMed Inc. (RMD) was 530,016 shares, as reported at the end of Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.